Efficacy of JOINS on Cartilage Protection in Knee Osteoarthritis: Prospective Randomized Controlled Trial

Joong Il Kim, Ja Young Choi, Kwang Gi Kim, Myung Chul Lee, Joong Il Kim, Ja Young Choi, Kwang Gi Kim, Myung Chul Lee

Abstract

Purpose: In this study, we compared the clinical efficacy of JOINS (SKI306X, SK Chemicals) with placebo on cartilage protection using magnetic resonance imaging (MRI).

Materials and methods: Sixty-nine patients were randomized to the JOINS group (200 mg, three times daily for 1 year; n=33) or the placebo group (n=36). Changes in cartilage volume and thickness were measured using MRI. Changes in the delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) index, subchondral bone marrow abnormality scores, and clinical scores including knee pain visual analog scale (VAS) score and Korean Western Ontario and McMaster Universities Osteoarthritis Index (K-WOMAC) were also evaluated.

Results: Changes in cartilage thickness and volume and subarticular bone marrow abnormality scores were not different between groups. Changes in the dGEMRIC index in the lateral tibial plateau were greater in the JOINS group than in the placebo group (19.64±114.33 msec vs. -57.77±123.30 msec; p=0.011). Significantly greater changes in VAS were observed in the JOINS group than in the placebo group (-26.00±12.25 vs. -12.47±21.54; p=0.002) and K-WOMAC (-15.42 ± 7.73 vs. -8.15±13.71; p=0.003).

Conclusions: Compared with placebo, JOINS had superior clinical efficacy in regard to cartilage protection.

Keywords: Cartilage; Knee; Osteoarthritis; SKI306X.

Conflict of interest statement

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Flow diagram of the present study based on Consolidated Standards of Reporting Trials (CONSORT) guidelines.

References

    1. Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am. 2004;42:1–9. doi: 10.1016/S0033-8389(03)00161-1.
    1. Howell DS, Woessner JF, Jr, Jimenez S, Seda H, Schumacher HR., Jr A view on the pathogenesis of osteoarthritis. Bull Rheum Dis. 1978–1979;29:996–1001.
    1. Radin EL. Who gets osteoarthritis and why? An update. J Rheumatol. 2005;32:1136–8.
    1. Sharma L, Kapoor D, Issa S. Epidemiology of osteoarthritis: an update. CurrOpin Rheumatol. 2006;18:147–56.
    1. Bhatia D, Bejarano T, Novo M. Current interventions in the management of knee osteoarthritis. J Pharm Bioallied Sci. 2013;5:30–8. doi: 10.4103/0975-7406.106561.
    1. Bruyère O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, Hochberg MC, Kanis JA, Kvien TK, Martel-Pelletier J, Rizzoli R, Silverman S, Reginster JY. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Semin Arthritis Rheum. 2014;44:253–63. doi: 10.1016/j.semarthrit.2014.05.014.
    1. Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med. 1997;103(6A):25S–30S. doi: 10.1016/S0002-9343(97)90005-X.
    1. Bakowsky VS, Hanly JG. Complications of nonsteroidal antiiflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center. J Rheumatol. 1999;26:1557–63.
    1. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl. 1991;28:6–10.
    1. Murray MD, Brater DC. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med. 1990;112:559–60. doi: 10.7326/0003-4819-112-8-559.
    1. Roth SH. NSAID gastropathy: a new understanding. Arch Intern Med. 1996;156:1623–8. doi: 10.1001/archinte.1996.00440140039003.
    1. Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging. 2007;24:573–80. doi: 10.2165/00002512-200724070-00005.
    1. Hochberg MC. Nutritional supplements for knee osteoarthritis: still no resolution. N Engl J Med. 2006;354:858–60. doi: 10.1056/NEJMe058324.
    1. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010;30:357–63. doi: 10.1007/s00296-009-0969-5.
    1. Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675. doi: 10.1136/bmj.c4675.
    1. Cameron M, Gagnier JJ, Little CV, Parsons TJ, Blumle A, Chrubasik S. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part I: osteoarthritis. Phytother Res. 2009;23:1497–515. doi: 10.1002/ptr.3007.
    1. Cameron M, Gagnier JJ, Little CV, Parsons TJ, Blümle A, Chrubasik S. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 2: rheumatoid arthritis. Phytother Res. 2009;23:1647–62. doi: 10.1002/ptr.3006.
    1. Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytother Res. 2007;21:675–83. doi: 10.1002/ptr.2142.
    1. Ha CW, Park YB, Min BW, Han SB, Lee JH, Won YY, Park YS. Prospective, randomized, double-blinded, double-dummy and multicenter phase IV clinical study comparing the efficacy and safety of PG201 (Layla) and SKI306X in patients with osteoarthritis. J Ethnopharmacol. 2016;181:1–7. doi: 10.1016/j.jep.2016.01.029.
    1. Choi CH, Kim TH, Sung YK, Choi CB, Na YI, Yoo H, Jun JB. SKI306X inhibition of glycosaminoglycan degradation in human cartilage involves down-regulation of cytokine-induced catabolic genes. Korean J Intern Med. 2014;29:647–55. doi: 10.3904/kjim.2014.29.5.647.
    1. Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, Rhee HI, Ryu KH, Jung K, Han CK, Kwak WJ, Cho YB. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthritis Cartilage. 2002;10:471–8. doi: 10.1053/joca.2002.0526.
    1. Hartog A, Hougee S, Faber J, Sanders A, Zuurman C, Smit HF, van der Kraan PM, Hoijer MA, Garssen J. The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators. Phytomedicine. 2008;15:313–20. doi: 10.1016/j.phymed.2007.09.005.
    1. Kim JH, Ryu KH, Jung KW, Han CK, Kwak WJ, Cho YB. SKI306X suppresses cartilage destruction and inhibits the production of matrix metalloproteinase in rabbit joint cartilage explant culture. J Pharmacol Sci. 2005;98:298–306. doi: 10.1254/jphs.FPJ04058X.
    1. Peterfy CG, Guermazi A, Zaim S, Tirman PF, Miaux Y, White D, Kothari M, Lu Y, Fye K, Zhao S, Genant HK. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage. 2004;12:177–90. doi: 10.1016/j.joca.2003.11.003.
    1. Jung YB, Roh KJ, Jung JA, Jung K, Yoo H, Cho YB, Kwak WJ, Kim DK, Kim KH, Han CK. Effect of SKI 306X, a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee: a double-blind placebo controlled study. Am J Chin Med. 2001;29:485–91. doi: 10.1142/S0192415X01000502.
    1. Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011;70:982–9. doi: 10.1136/ard.2010.140848.
    1. Tiderius CJ, Olsson LE, Leander P, Ekberg O, Dahlberg L. Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) in early knee osteoarthritis. Magn Reson Med. 2003;49:488–92. doi: 10.1002/mrm.10389.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe